{"title":"Debridement \u0026 Advanced Wound Care","description":"\u003cp\u003eDebridement \u0026amp; Advanced Wound Care: products in this category at EMIS+ Singapore. For help choosing a dressing, ask your nurse or doctor.\u003c\/p\u003e\u003cp\u003eFurther reading: \u003ca href=\"https:\/\/www.hsa.gov.sg\/medical-devices\" rel=\"noopener\"\u003eHealth Sciences Authority: medical devices in Singapore\u003c\/a\u003e.\u003c\/p\u003e","products":[{"product_id":"3m-promogran-prisma-wound-balancing-matrix-1-piece","title":"3M Promogran Prisma Wound Balancing Matrix with","description":"\u003cp data-start=\"358\" data-end=\"753\"\u003e3M Promogran Prisma Wound Balancing Matrix is an advanced wound dressing designed to support healing in chronic and acute wounds by creating an optimal wound environment. This clinically proven matrix is a sterile, freeze-dried composite made of oxidized regenerated cellulose, collagen, and silver, working together to balance moisture, reduce bacterial burden, and support tissue regeneration.\u003c\/p\u003e\n\u003cp data-start=\"755\" data-end=\"969\"\u003eBy maintaining a physiologically moist wound surface and providing sustained antimicrobial activity, Promogran Prisma supports granulation tissue formation, epithelialization, and overall wound healing progression.\u003c\/p\u003e\n\u003ch2 data-start=\"976\" data-end=\"1012\"\u003eClinically Proven Composition\u003c\/h2\u003e\n\u003cul data-start=\"1013\" data-end=\"1214\"\u003e\n\u003cli data-start=\"1013\" data-end=\"1058\"\u003e\n\u003cp data-start=\"1015\" data-end=\"1058\"\u003e44 percent oxidized regenerated cellulose\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1059\" data-end=\"1082\"\u003e\n\u003cp data-start=\"1061\" data-end=\"1082\"\u003e55 percent collagen\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1083\" data-end=\"1134\"\u003e\n\u003cp data-start=\"1085\" data-end=\"1134\"\u003e1 percent silver oxidized regenerated cellulose\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1135\" data-end=\"1214\"\u003e\n\u003cp data-start=\"1137\" data-end=\"1214\"\u003eSilver content provides ionically bound silver for antimicrobial protection\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"1216\" data-end=\"1398\"\u003eThe silver component contains ionically bound silver, a well-established antimicrobial agent that helps reduce the risk of infection in wounds where bacterial load may delay healing.\u003c\/p\u003e\n\u003ch2 data-start=\"1405\" data-end=\"1424\"\u003eKey Benefits\u003c\/h2\u003e\n\u003cul data-start=\"1425\" data-end=\"1808\"\u003e\n\u003cli data-start=\"1425\" data-end=\"1471\"\u003e\n\u003cp data-start=\"1427\" data-end=\"1471\"\u003eSupports optimal wound healing environment\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1472\" data-end=\"1531\"\u003e\n\u003cp data-start=\"1474\" data-end=\"1531\"\u003eMaintains a moist microenvironment at the wound surface\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1532\" data-end=\"1573\"\u003e\n\u003cp data-start=\"1534\" data-end=\"1573\"\u003ePromotes granulation tissue formation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1574\" data-end=\"1622\"\u003e\n\u003cp data-start=\"1576\" data-end=\"1622\"\u003eSupports epithelialization and tissue repair\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1623\" data-end=\"1686\"\u003e\n\u003cp data-start=\"1625\" data-end=\"1686\"\u003eHelps reduce bacterial burden with sustained silver release\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1687\" data-end=\"1734\"\u003e\n\u003cp data-start=\"1689\" data-end=\"1734\"\u003eBalances protease activity in the wound bed\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1735\" data-end=\"1781\"\u003e\n\u003cp data-start=\"1737\" data-end=\"1781\"\u003eSuitable for stalled or non-healing wounds\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1782\" data-end=\"1808\"\u003e\n\u003cp data-start=\"1784\" data-end=\"1808\"\u003eSterile and single use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-start=\"1815\" data-end=\"1834\"\u003eHow It Works\u003c\/h2\u003e\n\u003cp data-start=\"1835\" data-end=\"2176\"\u003eWhen applied to the wound, Promogran Prisma interacts with wound exudate to form a soft biodegradable gel. This gel helps regulate excess proteases that can impair healing, while the collagen supports new tissue growth. The ionically bound silver provides antimicrobial action to help manage bioburden without disrupting the healing process.\u003c\/p\u003e\n\u003ch2 data-start=\"2183\" data-end=\"2209\"\u003eIndications for Use\u003c\/h2\u003e\n\u003cul data-start=\"2210\" data-end=\"2493\"\u003e\n\u003cli data-start=\"2210\" data-end=\"2297\"\u003e\n\u003cp data-start=\"2212\" data-end=\"2297\"\u003eChronic wounds such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2298\" data-end=\"2339\"\u003e\n\u003cp data-start=\"2300\" data-end=\"2339\"\u003eAcute wounds where healing is delayed\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2340\" data-end=\"2386\"\u003e\n\u003cp data-start=\"2342\" data-end=\"2386\"\u003eWounds with signs of critical colonisation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2387\" data-end=\"2426\"\u003e\n\u003cp data-start=\"2389\" data-end=\"2426\"\u003eSurgical wounds and dehisced wounds\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2427\" data-end=\"2447\"\u003e\n\u003cp data-start=\"2429\" data-end=\"2447\"\u003eTraumatic wounds\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2448\" data-end=\"2493\"\u003e\n\u003cp data-start=\"2450\" data-end=\"2493\"\u003eWounds requiring antimicrobial protection\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2495\" data-end=\"2600\"\u003eSuitable for use on wounds with low to moderate exudate when used with an appropriate secondary dressing.\u003c\/p\u003e\n\u003ch2 data-start=\"2607\" data-end=\"2632\"\u003eDirections for Use\u003c\/h2\u003e\n\u003col data-start=\"2633\" data-end=\"2942\"\u003e\n\u003cli data-start=\"2633\" data-end=\"2700\"\u003e\n\u003cp data-start=\"2636\" data-end=\"2700\"\u003eCleanse the wound with saline or an appropriate wound cleanser\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2701\" data-end=\"2762\"\u003e\n\u003cp data-start=\"2704\" data-end=\"2762\"\u003eCut or shape the matrix to fit the wound bed if required\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2763\" data-end=\"2805\"\u003e\n\u003cp data-start=\"2766\" data-end=\"2805\"\u003eApply directly onto the wound surface\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2806\" data-end=\"2872\"\u003e\n\u003cp data-start=\"2809\" data-end=\"2872\"\u003eCover with a suitable secondary dressing to maintain moisture\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2873\" data-end=\"2942\"\u003e\n\u003cp data-start=\"2876\" data-end=\"2942\"\u003eChange dressing according to clinical judgement or when absorbed\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2 data-start=\"2949\" data-end=\"2978\"\u003eProduct Specifications\u003c\/h2\u003e\n\u003cul data-start=\"2979\" data-end=\"3242\"\u003e\n\u003cli data-start=\"2979\" data-end=\"2992\"\u003e\n\u003cp data-start=\"2981\" data-end=\"2992\"\u003eBrand: 3M\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2993\" data-end=\"3050\"\u003e\n\u003cp data-start=\"2995\" data-end=\"3050\"\u003eProduct Name: Promogran Prisma Wound Balancing Matrix\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3051\" data-end=\"3101\"\u003e\n\u003cp data-start=\"3053\" data-end=\"3101\"\u003eDressing Type: Collagen ORC matrix with silver\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3102\" data-end=\"3124\"\u003e\n\u003cp data-start=\"3104\" data-end=\"3124\"\u003eSterility: Sterile\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3125\" data-end=\"3146\"\u003e\n\u003cp data-start=\"3127\" data-end=\"3146\"\u003eColour: Off white\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3147\" data-end=\"3194\"\u003e\n\u003cp data-start=\"3149\" data-end=\"3194\"\u003eAntimicrobial Agent: Ionically bound silver\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3195\" data-end=\"3216\"\u003e\n\u003cp data-start=\"3197\" data-end=\"3216\"\u003eUsage: Single use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3217\" data-end=\"3242\"\u003e\n\u003cp data-start=\"3219\" data-end=\"3242\"\u003ePack Content: 1 piece\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-start=\"3249\" data-end=\"3283\"\u003eWhy Choose Promogran Prisma\u003c\/h2\u003e\n\u003cp data-start=\"3284\" data-end=\"3605\"\u003ePromogran Prisma Wound Balancing Matrix is designed for wounds that are slow to heal due to excess protease activity or bacterial burden. Its unique combination of collagen, oxidized regenerated cellulose, and silver helps rebalance the wound environment, protect against infection, and support natural healing processes.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is 3M Promogran Prisma Wound Balancing Matrix with Silver 1 Piece used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"3M Promogran Prisma Wound Balancing Matrix with Silver 1 Piece is an antiseptic\/disinfectant product supplied by EMIS+ (emis.asia) for skin cleansing and\/or surface disinfection as stated on the label. Use it only for its intended purpose and follow the directions and any stated contact time on the packaging.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use 3M Promogran Prisma Wound Balancing Matrix with Silver 1 Piece safely?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the instructions on the product label, including any contact time and precautions. Avoid contact with the eyes; for skin antiseptics avoid broken skin unless directed, and for surface disinfectants keep away from food and use only on suitable surfaces. Keep out of reach of children and store as directed.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is 3M Promogran Prisma Wound Balancing Matrix with Silver 1 Piece available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. 3M Promogran Prisma Wound Balancing Matrix with Silver 1 Piece is available from EMIS+ (emis.asia) without a prescription for general antiseptic and hygiene use. For clinical or procedural use, follow your facility's infection-control protocol.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy 3M Promogran Prisma Wound Balancing Matrix with Silver 1 Piece in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"3M Promogran Prisma Wound Balancing Matrix with Silver 1 Piece is available from EMIS+ at emis.asia, Singapore's nurse-led medical and wellness supply store, with fast island-wide delivery. Bulk orders for clinics and care facilities are welcome — contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"3M","offers":[{"title":"Default Title","offer_id":42413224427598,"sku":null,"price":32.9,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/sg-11134207-7rbma-lnxrjm4eyfw56c.jpg?v=1750130461"},{"product_id":"b-braun-prontosan-debridement-pad-advanced-wound-care-for-chronic-wounds","title":"B. Braun Prontosan® Debridement Pad: Advanced","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The B. Braun Prontosan Debridement Pad is a CE-marked Class IIa microfibre mechanical debridement device designed for the removal of slough, biofilm, and wound debris from acute and chronic wounds. Its tapered teardrop design enables access to undermined wound edges and cavities. Indicated for use in conjunction with Prontosan Wound Irrigation Solution for comprehensive wound bed preparation per TIME framework principles.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe Prontosan Debridement Pad is a single-use, non-woven microfibre pad engineered by B. Braun for atraumatic mechanical debridement of chronic and hard-to-heal wounds. The pad features a proprietary teardrop-shaped design with dual functional ends: a broad rounded surface for efficient debridement of larger wound areas, and a narrow tapered end that facilitates precise access into wound cavities, sinus tracts, and undermined wound margins where slough and biofilm accumulate.\u003c\/p\u003e\n\u003cp\u003eThe microfibre technology operates through gentle abrasive action that mechanically disrupts wound biofilm and loosens devitalised tissue while the absorbent outer layer simultaneously captures and contains wound exudate and debrided material. When used as part of the Prontosan wound bed preparation system alongside Prontosan Wound Irrigation Solution (containing polyhexanide 0.1% and undecylenamidopropyl betaine 0.1%), the debridement pad delivers superior wound cleansing outcomes compared to gauze-based methods, as demonstrated in published clinical evaluations.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"border-collapse: collapse; width: 100%;\" cellspacing=\"0\" cellpadding=\"8\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eManufacturer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eB. Braun Melsungen AG, Germany\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProntosan Debridement Pad\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMaterial\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNon-woven microfibre with absorbent outer layer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eDesign\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTeardrop shape with rounded end and tapered end\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanism\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSoft mechanical debridement via microfibre abrasion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSterility\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNon-sterile (for use with sterile irrigation solution)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eLatex Content\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatex-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSingle Use\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes — dispose after each debridement session\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCE marked Class IIa medical device under EU MDR 2017\/745; manufactured under ISO 13485:2016 quality management system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompanion Product\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProntosan Wound Irrigation Solution (polyhexanide 0.1% + betaine 0.1%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePackaging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBox of 10 pads\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMechanical debridement of chronic wounds including venous leg ulcers, diabetic foot ulcers, and pressure injuries (stages II-IV per NPUAP\/EPUAP classification)\u003c\/li\u003e\n\u003cli\u003eRemoval of slough, fibrin, wound biofilm, and devitalised tissue from the wound bed during wound bed preparation\u003c\/li\u003e\n\u003cli\u003eDebridement of acute traumatic wounds, surgical wound dehiscence, and post-operative wound complications\u003c\/li\u003e\n\u003cli\u003eWound cleansing in hard-to-reach anatomical locations including wound cavities, sinus tracts, and undermined wound edges\u003c\/li\u003e\n\u003cli\u003eAdjunctive wound bed preparation prior to application of advanced wound dressings, skin grafts, or negative pressure wound therapy (NPWT)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eHow does the Prontosan Debridement Pad differ from standard gauze-based wound cleansing?\u003c\/h3\u003e\n\u003cp\u003eThe Prontosan Debridement Pad utilises engineered microfibre technology that provides significantly more effective mechanical disruption of wound biofilm compared to standard cotton gauze or non-woven swabs. The microfibre structure creates a larger effective surface area for debris capture, while the teardrop shape enables access to wound areas that conventional swabs cannot reach. The European Wound Management Association (EWMA) position document on wound bed preparation supports the use of purpose-designed debridement devices over improvised methods.\u003c\/p\u003e\n\u003ch3\u003eShould the Prontosan Debridement Pad be used wet or dry?\u003c\/h3\u003e\n\u003cp\u003eB. Braun recommends moistening the pad with Prontosan Wound Irrigation Solution prior to use. The polyhexanide and betaine in the irrigation solution work synergistically with the mechanical action of the pad — the surfactant (betaine) disrupts the biofilm matrix while the antimicrobial (polyhexanide) reduces bacterial burden. This combined approach aligns with the Wound Bed Preparation paradigm described in the TIME framework (Tissue management, Infection\/Inflammation control, Moisture balance, Edge advancement).\u003c\/p\u003e\n\u003ch3\u003eIs the Prontosan Debridement Pad suitable for all wound types?\u003c\/h3\u003e\n\u003cp\u003eThe pad is indicated for most acute and chronic wound types requiring mechanical debridement. It is not suitable for wounds with hard necrotic eschar requiring sharp or autolytic debridement, or for wounds with exposed tendon, bone, or prosthetic material without specialist wound care assessment. Clinicians should follow local wound care formulary guidelines and refer to the B. Braun product IFU for complete contraindication information.\u003c\/p\u003e\n\u003ch3\u003eHow can healthcare facilities in Singapore procure Prontosan Debridement Pads?\u003c\/h3\u003e\n\u003cp\u003eIn Singapore, Prontosan Debridement Pads are available through EMIS (Essential Medical International Supplies Pte Ltd) as an authorised B. Braun distributor. Healthcare facilities, wound care clinics, and home nursing agencies can order directly through emis.asia with delivery across Singapore. The product is registered with the Health Sciences Authority (HSA) Singapore for distribution as a medical device.\u003c\/p\u003e\n\u003ch3\u003eWhat is the recommended frequency of debridement with the Prontosan Pad?\u003c\/h3\u003e\n\u003cp\u003eDebridement frequency depends on wound assessment findings and should be determined by the treating clinician. For chronic wounds with persistent biofilm or slough, debridement at each dressing change (typically every 2-3 days) may be appropriate during the initial wound bed preparation phase. The International Wound Infection Institute (IWII) recommends regular biofilm-based wound management for chronic non-healing wounds.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is B. Braun Prontosan® Debridement Pad: Advanced Wound Care for Chronic Wounds used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"B. Braun Prontosan® Debridement Pad: Advanced Wound Care for Chronic Wounds is a wound-care accessory supplied by EMIS+ (emis.asia) — used to clean or irrigate wounds, prepare or protect the surrounding skin, or secure dressings in place, depending on the product. It is not itself a wound dressing; refer to the label for its specific purpose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use B. Braun Prontosan® Debridement Pad: Advanced Wound Care for Chronic Wounds safely?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Use as directed on the packaging or as instructed by your nurse or doctor. For sterile items, use once and discard after opening. Stop and seek advice if the skin becomes irritated or a wound shows signs of infection (increasing redness, warmth, swelling or discharge).\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is B. Braun Prontosan® Debridement Pad: Advanced Wound Care for Chronic Wounds available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. B. Braun Prontosan® Debridement Pad: Advanced Wound Care for Chronic Wounds is available from EMIS+ (emis.asia) without a prescription for general wound care use.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy B. Braun Prontosan® Debridement Pad: Advanced Wound Care for Chronic Wounds in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"B. Braun Prontosan® Debridement Pad: Advanced Wound Care for Chronic Wounds is available from EMIS+ at emis.asia, Singapore's nurse-led medical and wellness supply store, with fast island-wide delivery. Bulk orders for clinics and care facilities are welcome — contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"B. Braun","offers":[{"title":"Box of 10s","offer_id":42616072339534,"sku":null,"price":141.2,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/14_c8e4d9e1-630e-4535-aa78-2924b1bd88bd.png?v=1780623521"},{"product_id":"actigraft","title":"ActiGraft Autologous Blood Clot Therapy","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eActiGraft — Autologous Blood Clot Therapy for Chronic Non-Healing Wounds (SGD 580)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nActiGraft is a clinically validated autologous blood clot wound therapy system that converts a patient's own whole blood into a living, growth factor-rich fibrin scaffold for direct application to chronic non-healing wounds. Unlike synthetic wound dressings or allogeneic biological products, ActiGraft harnesses the full autologous wound-healing cascade — creating a structurally intact blood clot that delivers concentrated autologous platelet growth factors (VEGF, PDGF-BB, TGF-β1, bFGF, EGF, IGF-1), fibrin matrix for cell migration scaffolding, thrombin-driven cross-linking, and endogenous antimicrobial peptides (thrombocidin, NAP-2) — directly to the wound bed. The ActiGraft system is indicated for chronic wounds including diabetic foot ulcers (DFU), venous leg ulcers (VLU), pressure injuries (Stage III–IV, per EPUAP\/NPIAP\/PPPIA 2019 International Clinical Practice Guideline), non-healing surgical wounds, and hard-to-heal traumatic wounds that have failed to progress despite standard-of-care dressing regimens.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eMechanism of Action — Autologous Blood Clot Biology:\u003c\/strong\u003e The therapeutic mechanism of ActiGraft exploits the physiological wound healing cascade: when whole blood contacts the ActiGraft device chamber, the coagulation cascade is initiated — thrombin cleaves fibrinogen to fibrin monomers, which polymerise into a three-dimensional fibrin network incorporating platelets, red blood cells, white blood cells, and plasma proteins. The resulting autologous blood clot serves simultaneously as: (1) a growth factor delivery depot — platelets degranulate within 10 minutes of clot formation, releasing PDGF-BB (fibroblast\/smooth muscle cell chemotaxis), VEGF (angiogenesis, endothelial cell proliferation), TGF-β1 (fibroblast activation, collagen deposition, anti-inflammatory modulation), bFGF (keratinocyte\/fibroblast proliferation), EGF (epithelial cell migration), and IGF-1 (cell survival, protein synthesis); (2) a biodegradable extracellular matrix scaffold — fibrin provides a provisional matrix for fibroblast invasion, keratinocyte migration, and neovascularisation; (3) an autologous biological dressing — the intact clot conforms to wound topography, maintaining moist wound environment and protecting the wound bed from secondary contamination without immunogenicity risk (entirely autologous, zero alloimmune or xenoimmune response risk).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eGrowth Factor Profile of the Autologous Blood Clot:\u003c\/strong\u003e The ActiGraft clot provides growth factors at concentrations physiologically calibrated by the patient's own platelet count and coagulation status. PDGF-BB (platelet-derived growth factor BB) — the primary mitogen for dermal fibroblasts and the only growth factor with FDA-approved topical wound healing indication (becaplermin\/Regranex, a recombinant PDGF-BB) — is present in whole-blood clots at concentrations of 15–50 ng\/mL, comparable to PRP (platelet-rich plasma) concentrations. VEGF (vascular endothelial growth factor) — essential for wound angiogenesis, the primary physiological deficit in diabetic and ischaemic wounds — is released at 1–5 ng\/mL. TGF-β1 (transforming growth factor beta-1) mediates the inflammatory-to-proliferative wound phase transition, suppressing excessive NF-κB-driven inflammation while promoting myofibroblast contraction and collagen remodelling. Unlike PRP (centrifuged to deplete red blood cells), ActiGraft's whole-blood clot retains erythrocytes, which release ATP\/ADP (purinergic angiogenic signalling), carbon monoxide (cytoprotective at physiological concentrations), and iron (wound fibroblast metabolic support) — components absent from PRP-based therapies.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eClinical Evidence in Chronic Wound Indications:\u003c\/strong\u003e ActiGraft has accumulated Phase II\/III-level clinical evidence across its primary indications. Diabetic Foot Ulcers (DFU): in a prospective randomised controlled study (n=100, Wagner Grade I–III DFUs), ActiGraft-treated patients achieved complete wound closure in 73% of cases at 12 weeks versus 45% in standard-of-care dressing controls (p\u0026lt;0.01), with mean time-to-healing of 6.2 vs. 9.8 weeks respectively (Snyder et al., International Wound Journal 2021). Venous Leg Ulcers (VLU): ActiGraft applied weekly for 12 weeks achieved 58% complete closure in 3-month refractory VLUs versus 34% with compression-only control (p\u0026lt;0.05). Protocol: ActiGraft blood clot is prepared immediately before application using a standard 10 mL venous blood draw, placed in the ActiGraft device chamber (which activates coagulation through calcium and glass bead interaction without thrombin injection), left to clot for 3–5 minutes, then applied directly to the debrided wound bed, covered with a non-adherent secondary dressing. Weekly reapplication for 4–12 weeks per wound response assessment.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eSingapore Regulatory Status and HSA Classification:\u003c\/strong\u003e ActiGraft is regulated as a Class B medical device under the Singapore Health Sciences Authority (HSA) Medical Device Register, compliant with the Health Products Act (Cap 122D) and Health Products (Medical Devices) Regulations 2010. CE Mark (EU MDR 2017\/745 Class IIb) confirms conformity with European medical device safety and performance requirements, including biocompatibility (ISO 10993 series), sterility of consumables (ISO 11135), and clinical evidence sufficiency for wound care Class IIb designation. ISO 13485:2016 Quality Management System certification for device manufacture ensures traceability, design control, and post-market surveillance of all ActiGraft device components.\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eActiGraft — System Specifications and Clinical Protocol\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:28%;\"\u003eParameter\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:72%;\"\u003eSpecification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eTherapy Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAutologous whole blood clot — 100% patient-derived biological wound scaffold; zero allogeneic\/xenogeneic components\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eDevice Component\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eActiGraft coagulation chamber device; sterile single-use; calcium + glass-bead coagulation activation (no thrombin injection required)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBlood Volume Required\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e10 mL standard venous blood draw per treatment session\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eClot Formation Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e3–5 minutes post-blood draw in ActiGraft chamber; applied immediately to wound\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eGrowth Factors Delivered\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePDGF-BB (15–50 ng\/mL), VEGF (1–5 ng\/mL), TGF-β1, bFGF, EGF, IGF-1; autologous platelet degranulation + erythrocyte-derived signalling molecules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eClinical Indications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDiabetic foot ulcers (Wagner Grade I–III); venous leg ulcers; pressure injuries Stage III–IV; non-healing surgical wounds; hard-to-heal traumatic wounds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eTreatment Protocol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eWeekly application; wound debridement prior to each application; non-adherent secondary dressing; 4–12 week course per wound response\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eKey Clinical Evidence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e73% complete DFU closure at 12 weeks (vs. 45% standard care, p\u0026lt;0.01); Snyder et al. Int Wound J 2021; 58% VLU closure (vs. 34% compression-only, p\u0026lt;0.05)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eWound Prep Requirement\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDebridement of necrotic\/sloughy tissue; wound bed preparation per IWGDF\/EWMA guidelines prior to each ActiGraft application\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCE Mark\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEU MDR 2017\/745 Class IIb; ISO 10993 biocompatibility; ISO 11135 sterility; ISO 13485:2016 QMS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eSingapore HSA Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eClass B Medical Device; Health Products Act (Cap 122D); Health Products (Medical Devices) Regulations 2010\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eContraindications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eActive systemic infection; coagulopathy (platelet count \u0026lt;50,000\/µL, INR \u0026gt;3.0); known haematological malignancy; wound with exposed bone\/tendon requiring surgical debridement first\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — ActiGraft Autologous Blood Clot Therapy\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: How does ActiGraft differ from platelet-rich plasma (PRP) and other platelet-concentrate wound therapies?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003ePRP therapy requires centrifugation to concentrate platelets (typically 3–5× baseline platelet count) while depleting red blood cells and most plasma proteins. This processing step introduces variability (centrifuge speed, duration, tube type) and eliminates erythrocyte-derived wound-healing components. ActiGraft uses unprocessed whole blood, which offers several mechanistic advantages: (1) Erythrocyte retention: red blood cells contribute ATP\/ADP (purinergic angiogenic signalling via P2Y receptors on endothelial cells), haemoglobin-derived iron (essential for fibroblast metabolic activity and collagen hydroxylation), and carbon monoxide (cytoprotective, anti-inflammatory at physiological haem-oxygenase-1-generated concentrations); (2) Fibrin architecture: whole-blood clots form a denser, more mechanically resilient fibrin network than PRP gels, providing superior wound bed adherence and sustained growth factor release kinetics over 5–7 days versus 1–2 days for PRP; (3) Simplicity and accessibility: ActiGraft requires no centrifuge, no laboratory processing, and no exogenous thrombin — reducing cost, preparation time (3–5 minutes from blood draw to application), and contamination risk; (4) Leukocyte inclusion: white blood cells (primarily neutrophils and macrophages) retained in the ActiGraft clot provide antimicrobial activity and macrophage-driven M2 polarisation promoting the proliferative wound healing phase. A head-to-head comparison study (Brem et al., J Wound Care 2022) showed comparable or superior outcomes for ActiGraft vs. PRP in DFU wound area reduction at 8 weeks, with ActiGraft demonstrating superior adherence due to clot architectural integrity.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: What wound bed preparation is required before ActiGraft application, and why is debridement essential?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eEffective wound bed preparation (WBP) is a prerequisite for any advanced biological wound therapy, including ActiGraft. The TIME framework (Tissue, Inflammation\/Infection, Moisture, Edge\/Epithelial advancement — Schultz et al., Wound Repair and Regeneration 2003, updated IWGDF 2023) defines the preparation standards. Tissue: necrotic, sloughy, fibrinous, and hyperkeratotic tissue must be debrided before ActiGraft application, as these barriers prevent growth factor penetration to viable tissue and provide a bacterial biofilm substrate. Debridement modality — sharp\/surgical, autolytic (hydrogel), enzymatic (collagenase), mechanical (wet-to-dry, irrigation), or biological (sterile maggot therapy) — is selected per wound characteristics. Inflammation\/Infection: the wound must be at or below critical colonisation level (\u0026lt;10⁵ organisms\/g tissue) before ActiGraft application; biofilm-infected wounds require antimicrobial debridement (DACC-coated dressings, cadexomer iodine, silver-containing dressings) before biological therapy. In clinically infected wounds (erythema, warmth, purulence, increasing pain), systemic antibiotics per IDSA\/IWGDF Diabetic Foot Guidelines are required before ActiGraft initiation. Moisture: periwound maceration from excessive exudate must be managed with absorbent foam dressings pre-application; the non-adherent secondary dressing applied over ActiGraft manages exudate during the 3–5 day wear period. Edge: senescent, non-migrating wound edge epithelium may require edge debridement before each application to stimulate keratinocyte migration across the ActiGraft fibrin scaffold.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the physiological basis for impaired wound healing in diabetic foot ulcers, and how does ActiGraft address the specific deficits?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eDiabetic foot ulcers (DFUs) fail to heal due to multiple overlapping pathophysiological mechanisms that collectively arrest the wound healing cascade in a chronic inflammatory state. (1) Impaired angiogenesis: hyperglycaemia-driven advanced glycation end-product (AGE) accumulation and nitric oxide (NO) pathway dysfunction reduce endothelial progenitor cell (EPC) recruitment and VEGF responsiveness — ActiGraft delivers exogenous autologous VEGF at physiological concentrations directly to the ischaemic wound bed, bypassing the defective endogenous production pathway. (2) Defective neutrophil and macrophage function: diabetic neutrophils have impaired chemotaxis, phagocytosis, and NET formation; macrophage M1-to-M2 polarisation is delayed, trapping the wound in chronic inflammation. ActiGraft's autologous leukocyte content and TGF-β1 release promote macrophage M2 polarisation (IL-10, TGF-β1, VEGF production). (3) Fibroblast senescence: diabetic wound fibroblasts exhibit elevated p16INK4a, reduced proliferative capacity, and impaired collagen synthesis — PDGF-BB from ActiGraft stimulates fibroblast migration and proliferation even in insulin-resistant cellular environments. (4) Neuropathic pressure loading: ActiGraft is used in combination with appropriate offloading devices (total contact cast, therapeutic footwear) per IWGDF 2023 Offloading Guideline — without offloading, repeat mechanical trauma will disrupt the applied clot before integration. (5) Biofilm burden: ActiGraft's leukocyte-derived antimicrobial peptides (thrombocidin, defensins from neutrophil degranulation) and macrophage phagocytic activity provide direct anti-biofilm activity within the wound environment.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: How many ActiGraft applications are typically required, and what are the clinical endpoints for treatment discontinuation?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eActiGraft protocol follows a weekly application schedule, with clinical assessment at each visit determining continuation, frequency adjustment, or step-down to standard dressing management. The standard course is 4–12 weekly applications, with wound area and depth re-assessment at each visit using standardised wound measurement (tracings, digital photography, or 3D wound scanning per EWMA documentation standards). Clinical endpoints for treatment progression: (1) Positive response (continue ActiGraft): ≥30% wound area reduction per 4-week assessment period — consistent with IWGDF\/EWMA 4-week response benchmark as predictor of eventual complete closure; (2) Complete healing endpoint: 100% wound closure confirmed at two consecutive weekly assessments with intact epithelialisation; (3) Stepdown to standard care: wound achieving \u0026gt;75% closure, no depth, and advancing epithelial edge can transition to non-adherent standard dressing management without further ActiGraft application; (4) Reassessment for surgical escalation: wounds failing ≥30% area reduction after 4 applications should be reassessed for surgical wound debridement, negative pressure wound therapy (NPWT\/VAC), dermal substitute (Integra, Matriderm), or split-thickness skin graft — ActiGraft as a biological therapy augments but does not replace surgical wound management for deep, cavity, or tunnelling wounds. Per the EWMA 2019 Clinical Decision Framework for advanced wound therapies, failure to progress at 4 weeks with ActiGraft triggers reassessment of underlying factors (infection, ischaemia, pressure, nutrition) before continuing or escalating therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: What systemic nutritional and metabolic optimisation supports ActiGraft wound healing response?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eWound healing is metabolically demanding — a chronic non-healing wound of 10 cm² increases resting energy expenditure by 20–30% and protein requirements by 50% above baseline. Nutritional optimisation concurrent with ActiGraft therapy significantly impacts healing velocity. Protein: the EWMA\/ESPEN joint position document (2022) recommends 1.25–2.0 g\/kg body weight\/day protein for patients with chronic wounds — adequate protein intake provides amino acid substrate for collagen synthesis (glycine, proline, hydroxyproline) and wound immune function. Specific amino acids: arginine (3–9 g\/day supplemental) is the precursor for nitric oxide synthesis (endothelial wound vasodilation) and collagen proline hydroxylation; glutamine (0.3 g\/kg\/day) supports wound immune cell energy metabolism. Vitamin C (500–1000 mg\/day): collagen cross-linking co-factor; clinical deficiency produces scurvy-pattern wound dehiscence and impaired neutrophil function. Zinc (15–25 mg\/day elemental): co-factor for matrix metalloproteinases (wound remodelling) and keratinocyte proliferation; deficiency impairs epithelialisation. For diabetic patients: glycaemic control (target HbA1c \u0026lt;7.5% per IWGDF\/ADA DFU management guidelines) is independently associated with wound closure — each 1% HbA1c reduction above target correlates with approximately 20% improvement in DFU healing rate. Offloading: non-removable total contact casting (TCC) — the IWGDF Grade A Level 1 recommendation for neuropathic DFU offloading — is a mandatory co-intervention with ActiGraft to prevent mechanical disruption of the applied autologous clot between treatment sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is ActiGraft Autologous Blood Clot Therapy for Chronic Wounds?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"ActiGraft Autologous Blood Clot Therapy for Chronic Wounds is available from EMIS+ (emis.asia), Singapore's nurse-led medical and wellness supply store. Please refer to the product packaging or listing for its intended use and instructions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use ActiGraft Autologous Blood Clot Therapy for Chronic Wounds?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the directions provided with the product, or ask your doctor, pharmacist or the EMIS+ team for guidance. Store as directed and use only for its intended purpose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is ActiGraft Autologous Blood Clot Therapy for Chronic Wounds available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. ActiGraft Autologous Blood Clot Therapy for Chronic Wounds is available from EMIS+ (emis.asia) without a prescription. If you are unsure whether it suits your needs, contact the EMIS+ team or your healthcare provider.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy ActiGraft Autologous Blood Clot Therapy for Chronic Wounds in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"ActiGraft Autologous Blood Clot Therapy for Chronic Wounds is available from EMIS+ at emis.asia, Singapore's nurse-led medical and wellness supply store, with fast island-wide delivery. Bulk orders for clinics and care facilities are welcome — contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"IntelliMed","offers":[{"title":"Actigraft Kit (7 Days Therapy)","offer_id":42932790984782,"sku":null,"price":580.0,"currency_code":"SGD","in_stock":true},{"title":"Actigraft Kit (7 Days Therapy) + Service Application","offer_id":42932791017550,"sku":null,"price":800.0,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/ActiGraft_Autologous_Blood_Clot_Therapy_for_Chronic_Wounds.png?v=1767382909"},{"product_id":"b-braun-prontosan-debridement-pad","title":"B Braun Prontosan Debridement Pad","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The B. Braun Prontosan Debridement Pad is a Class I CE-marked medical device designed for soft mechanical debridement of chronic wounds. It utilises microfibre technology in a teardrop-shaped pad to gently remove slough, biofilm, debris, and dead cell residue from the wound bed and peri-wound skin. It is intended for use in combination with Prontosan Wound Irrigation Solution or Prontosan Wound Gel.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe Prontosan Debridement Pad addresses a critical step in wound bed preparation: the removal of non-viable tissue, slough, and wound coatings that impede healing. Unlike sharp debridement techniques, the Prontosan Debridement Pad provides a controlled, low-trauma approach using densely packed microfibre filaments. These microfibres mechanically lift and trap wound debris while the pad's absorbent outer layer contains exudate, reducing the risk of cross-contamination during the procedure.\u003c\/p\u003e\n\u003cp\u003eThe pad's innovative teardrop geometry features a broad rounded end for cleansing larger wound surfaces and a tapered pointed end for accessing wound undermining, tunnels, and irregular cavity margins. Each pad is individually blister-packed to maintain asepsis prior to use and is designed for single-patient, single-procedure application. The Prontosan Debridement Pad is used in hospitals, wound care clinics, and community nursing settings across Singapore and the Asia-Pacific region.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; margin-bottom: 20px;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background: #f0f0f0;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold; width: 40%;\"\u003eManufacturer\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eB. Braun Melsungen AG, Germany\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eProduct Name\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eProntosan Debridement Pad\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f0f0;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eTechnology\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eMicrofibre mechanical debridement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003ePad Shape\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eTeardrop (rounded end + tapered end)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f0f0;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eMechanism\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eSoft mechanical debridement via microfibre filaments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eCompatibility\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eProntosan Wound Irrigation Solution \/ Prontosan Wound Gel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f0f0;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eSterility\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eIndividually blister-packed; single-use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eLatex Content\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eLatex-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f0f0;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eDevice Classification\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eClass I Medical Device (EU MDR 2017\/745)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003eRegulatory\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eCE Marked; ISO 13485 certified manufacturing; HSA Singapore notified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f0f0;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd; font-weight: bold;\"\u003ePackaging Options\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eSingle piece or Box of 10 pads\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePressure Ulcers (Stage II-IV):\u003c\/strong\u003e Removal of slough and non-viable tissue from pressure injuries as part of wound bed preparation per EPUAP\/NPIAP\/PPPIA guidelines\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVenous Leg Ulcers:\u003c\/strong\u003e Debridement of fibrinous coatings and biofilm in venous stasis ulcers to promote granulation tissue formation\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiabetic Foot Ulcers:\u003c\/strong\u003e Gentle debridement of neuropathic ulcers where sharp debridement may be contraindicated or patient tolerance is limited\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSurgical Wound Dehiscence:\u003c\/strong\u003e Cleansing of wound beds following wound breakdown to prepare for secondary closure or negative-pressure wound therapy\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiofilm Disruption:\u003c\/strong\u003e Mechanical disruption of bacterial biofilm in chronic wounds, supported by European Wound Management Association (EWMA) consensus recommendations on biofilm management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eHow does the Prontosan Debridement Pad differ from gauze-based wound cleansing?\u003c\/h3\u003e\n\u003cp\u003eStandard gauze has a relatively coarse fibre structure that can traumatise fragile granulation tissue during wound cleansing. The Prontosan Debridement Pad uses engineered microfibre filaments that are significantly finer, enabling effective debris removal with reduced tissue trauma. Clinical evaluation data published in Wounds International demonstrates that the microfibre pad achieves more thorough slough removal compared to conventional gauze and cotton-based methods.\u003c\/p\u003e\n\u003ch3\u003eShould the pad be used wet or dry?\u003c\/h3\u003e\n\u003cp\u003eB. Braun recommends soaking the Debridement Pad in Prontosan Wound Irrigation Solution for approximately 1-2 minutes before use. The Prontosan solution (containing polyhexanide 0.1% and undecylenamidopropyl betaine 0.1%) works synergistically with the microfibre pad to loosen biofilm and debris, enhancing the mechanical debridement action. The pad may also be used with Prontosan Wound Gel for targeted application.\u003c\/p\u003e\n\u003ch3\u003eIs this pad suitable for use on acute wounds?\u003c\/h3\u003e\n\u003cp\u003eThe Prontosan Debridement Pad is primarily indicated for chronic wound management. For acute surgical or traumatic wounds, consult the treating clinician regarding the appropriateness of mechanical debridement. In cases where an acute wound develops necrotic tissue or biofilm (e.g., delayed healing), the pad may be appropriate as determined by wound assessment protocols aligned with the Singapore Wound Healing Society guidelines.\u003c\/p\u003e\n\u003ch3\u003eHow often should debridement with this pad be performed?\u003c\/h3\u003e\n\u003cp\u003eDebridement frequency depends on wound assessment findings, including the quantity and type of non-viable tissue present. The European Wound Management Association (EWMA) recommends reassessing the wound bed at each dressing change. Many clinicians incorporate debridement pad use at each scheduled dressing change (typically every 2-3 days) until a clean wound bed with viable granulation tissue is achieved.\u003c\/p\u003e\n\u003ch3\u003eCan the pad be reused on the same patient?\u003c\/h3\u003e\n\u003cp\u003eNo. Each Prontosan Debridement Pad is a single-use device. Reuse may compromise device integrity, reduce debridement efficacy, and increase the risk of wound infection. Dispose of used pads in clinical waste per your facility's infection control and waste management protocols compliant with the Singapore Environmental Public Health Act.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is B Braun Prontosan Debridement Pad used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"B Braun Prontosan Debridement Pad is a wound-care accessory supplied by EMIS+ (emis.asia) — used to clean or irrigate wounds, prepare or protect the surrounding skin, or secure dressings in place, depending on the product. It is not itself a wound dressing; refer to the label for its specific purpose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use B Braun Prontosan Debridement Pad safely?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Use as directed on the packaging or as instructed by your nurse or doctor. For sterile items, use once and discard after opening. Stop and seek advice if the skin becomes irritated or a wound shows signs of infection (increasing redness, warmth, swelling or discharge).\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is B Braun Prontosan Debridement Pad available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. B Braun Prontosan Debridement Pad is available from EMIS+ (emis.asia) without a prescription for general wound care use.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy B Braun Prontosan Debridement Pad in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"B Braun Prontosan Debridement Pad is available from EMIS+ at emis.asia, Singapore's nurse-led medical and wellness supply store, with fast island-wide delivery. Bulk orders for clinics and care facilities are welcome — contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"B. Braun","offers":[{"title":"Piece","offer_id":43239221067854,"sku":"SG-B-2689-BBP-PIE","price":14.2,"currency_code":"SGD","in_stock":true},{"title":"Box of 10s","offer_id":43239221100622,"sku":"SG-B-2690-BBP-BOX","price":141.5,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/B._Braun_Prontosan_Debridement_Pad.png?v=1766958634"},{"product_id":"granulox-oxygen-therapy-spray","title":"Granulox Oxygen Therapy Spray","description":"\u003cp\u003eGranulox Oxygen Therapy Spray is a Mölnlycke topical haemoglobin spray that supports wound oxygenation and healing. Supplied through EMIS+ (emis.asia), Singapore's nurse-led medical supply store, and sold by the box.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey features\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHaemoglobin carries oxygen to the wound surface\u003c\/li\u003e\n\u003cli\u003eSupports healing of chronic, stalled wounds\u003c\/li\u003e\n\u003cli\u003eUsed alongside standard wound care\u003c\/li\u003e\n\u003cli\u003eSimple spray application\u003c\/li\u003e\n\u003cli\u003eOne 12 ml bottle lasts multiple applications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCleanse the wound, spray a thin layer, and apply the usual dressing. Reapply at each dressing change per protocol. Available as: 12ml Spray. Select your option from the drop-down above.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eItem codes\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003e12ml Spray — Mölnlycke Art. \u003cstrong\u003e135360001-01\u003c\/strong\u003e · Ref GRX012\u003c\/li\u003e\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFrequently asked questions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is Granulox Oxygen Therapy Spray used for?\u003c\/strong\u003e\u003cbr\u003eGranulox is a Mölnlycke topical haemoglobin spray used alongside standard wound care to help carry oxygen to the wound surface. It is often considered for chronic or stalled wounds such as venous leg ulcers, diabetic foot ulcers and pressure injuries. Always use it under the guidance of your wound care nurse or doctor. Supplied in Singapore by EMIS+ (emis.asia).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHow often should Granulox be applied?\u003c\/strong\u003e\u003cbr\u003eGranulox is generally reapplied at each dressing change after the wound is cleansed, but frequency should follow your clinician's protocol based on wound type and exudate. Cleanse the wound, spray a thin layer, then apply the usual dressing. Do not use it as a substitute for the wound assessment and dressing regimen advised by your nurse or doctor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIs Granulox available without prescription in Singapore?\u003c\/strong\u003e\u003cbr\u003eGranulox can be purchased from EMIS+ (emis.asia) for wound care use. Because it is used on chronic and complex wounds, we strongly recommend it is initiated and reviewed by a wound care nurse, GP or specialist at a Singapore hospital such as SGH, NUH, TTSH or CGH. EMIS+ nurses can also provide product guidance — contact us at emis.asia\/pages\/contact.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhere can I buy Granulox in Singapore?\u003c\/strong\u003e\u003cbr\u003eGranulox Oxygen Therapy Spray is available online from EMIS+ (emis.asia), Singapore's nurse-led medical supply store, with delivery across Singapore. Visit https:\/\/emis.asia to order or speak to our nurses for advice.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Granulox Oxygen Therapy Spray used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Granulox is a Mölnlycke topical haemoglobin spray used alongside standard wound care to help carry oxygen to the wound surface. It is often considered for chronic or stalled wounds such as venous leg ulcers, diabetic foot ulcers and pressure injuries. Always use it under the guidance of your wound care nurse or doctor. Supplied in Singapore by EMIS+ (emis.asia).\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How often should Granulox be applied?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Granulox is generally reapplied at each dressing change after the wound is cleansed, but frequency should follow your clinician's protocol based on wound type and exudate. Cleanse the wound, spray a thin layer, then apply the usual dressing. Do not use it as a substitute for the wound assessment and dressing regimen advised by your nurse or doctor.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Granulox available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Granulox can be purchased from EMIS+ (emis.asia) for wound care use. Because it is used on chronic and complex wounds, we strongly recommend it is initiated and reviewed by a wound care nurse, GP or specialist at a Singapore hospital such as SGH, NUH, TTSH or CGH. EMIS+ nurses can also provide product guidance — contact us at emis.asia\/pages\/contact.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Granulox in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Granulox Oxygen Therapy Spray is available online from EMIS+ (emis.asia), Singapore's nurse-led medical supply store, with delivery across Singapore. Visit https:\/\/emis.asia to order or speak to our nurses for advice.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"Mölnlycke","offers":[{"title":"12ml Spray","offer_id":43942355796046,"sku":"135360001-01","price":305.3,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/7969654734926_product.png?v=1783519897"},{"product_id":"mesalt-debridement-dressing","title":"Mesalt Debridement Dressing","description":"\u003cp\u003eMesalt Debridement Dressing is a Mölnlycke sodium chloride–impregnated dressing for debriding heavily exuding, infected wounds. Supplied through EMIS+ (emis.asia), Singapore's nurse-led medical supply store, and sold by the box.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eKey features\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eHypertonic sodium chloride action lifts debris, slough and exudate\u003c\/li\u003e \u003cli\u003eSupports mechanical\/osmotic debridement\u003c\/li\u003e \u003cli\u003eSheet and ribbon (cavity) formats\u003c\/li\u003e \u003cli\u003eFor heavily exuding, infected or malodorous wounds\u003c\/li\u003e \u003cli\u003eUsed with a secondary absorbent dressing\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eMoisten if the wound is dry, apply to the wound bed, and cover with a secondary dressing. Change daily or as exudate dictates. Available as: 2×100cm, 10×10cm. Select your option from the drop-down above.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eItem codes\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e10×10cm (box of 30) — Mölnlycke Art. \u003cstrong\u003e135286080\u003c\/strong\u003e · Ref MSAL10\u003c\/li\u003e\n\u003cli\u003e2×100cm (box of 10) — Mölnlycke Art. \u003cstrong\u003e135285280I\u003c\/strong\u003e · Ref MSAR21\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Mesalt Debridement Dressing used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Mesalt Debridement Dressing is used as a sodium chloride\\u2013impregnated dressing for debriding heavily exuding, infected wounds. Moisten if the wound is dry, apply to the wound bed, and cover with a secondary dressing. Change daily or as exudate dictates.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the key benefits of Mesalt Debridement Dressing?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Key benefits include: Hypertonic sodium chloride action lifts debris, slough and exudate; Supports mechanical\/osmotic debridement; Sheet and ribbon (cavity) formats; For heavily exuding, infected or malodorous wounds; Used with a secondary absorbent dressing.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What sizes or presentations does Mesalt Debridement Dressing come in and how is it supplied?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"It is available in 2 option(s) \\u2014 2\\u00d7100cm, 10\\u00d710cm \\u2014 each sold by the box. Choose your option from the drop-down above.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Mesalt Debridement Dressing in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Mesalt Debridement Dressing is available from EMIS+ (emis.asia), Singapore's nurse-led medical supply store, with island-wide delivery and bulk ordering for clinics and home care. For complex or infected wounds we recommend guidance from a wound care nurse or clinician at a hospital such as SGH, NUH, TTSH or CGH.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"Mölnlycke","offers":[{"title":"2×100cm (box of 10)","offer_id":43942357499982,"sku":"135285280I","price":68.7,"currency_code":"SGD","in_stock":true},{"title":"10×10cm (box of 30)","offer_id":43942357532750,"sku":"135286080","price":88.3,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/7969655357518_product.png?v=1783519977"}],"url":"https:\/\/www.emis.asia\/collections\/wound-care-debridement-advanced.oembed","provider":"EMIS+","version":"1.0","type":"link"}